There is an increasing pressure for the medical industry to confront the vital challenge of advancing manufacturing processes for cell and gene therapy. CGT is widely regarded as the future of medicine, but innovation is hindered by slow, laborious and expensive sterility testing. This whitepaper goes behind the scenes of a significant breakthrough for contamination detection in CGT monitoring. It tells the story of PureSentry, a prototype device for on-line, real-time detection.